Mandibular metastatic lung cancer: a rare case report with multimodal imaging.

Oral RadiolJul 30, 2026 (epub)
Case ReportOncology (Medical)Radiology (Diagnostic)Open access

Ichiro Ogura, Junya Ono, Tohru Akashiba et al.

✦ AI-curated · Sources linked

Case in brief

A 67-year-old man presented with left mandibular pain, swelling, and gingival redness. Imaging revealed a mass-like radiopacity in the mandible without bone destruction. Multimodal imaging, including CT, ultrasound, and MRI, indicated a malignant tumor. Histopathological analysis confirmed adenocarcinoma in both the mandible and the right upper lobe of the lung, leading to a diagnosis of mandibular metastatic lung adenocarcinoma.

Diagnostic / clinical pearl

This case highlights the importance of multimodal imaging in diagnosing oral metastatic tumors, which can present atypically without bone destruction.

Source

PubMed · PMID 42533196Free full text on PubMed Central

Published in Oral Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.